Plain-English translation of NCT07623473 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The NIMBLE study is testing whether special blood tests can help doctors more accurately predict whether a lung nodule (a small spot found on a chest scan) is cancer. By analyzing your blood for specific markers and tumor-related DNA, researchers hope to improve the risk assessment that currently relies mainly on imaging and patient characteristics.
When a lung nodule is found, doctors currently must decide whether to perform invasive procedures like biopsies to determine if it's cancer. These invasive procedures carry real risks, including collapsed lung, bleeding, and infection. This study aims to add accurate blood tests to the decision-making process so fewer patients need to undergo these risky procedures.
You likely qualify if…
You likely don't qualify if…
When you are referred to the pulmonology department for evaluation, you will be asked to have an additional blood draw as part of the study. Your blood sample will be analyzed using a range of tests, including standard blood work, specialized proteins that may indicate lung cancer, and analysis of cell-free tumor DNA. Researchers will combine these blood results with your medical history and imaging findings using computer analysis to develop better prediction tools.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Denmark
Sponsor
Herlev and Gentofte Hospital
Collaborators
NEYE Foundation, Direktør Michael Hermann Nielsens mindelegat, afd B
Enrollment target
~1,800 participants
Started
May 2024
Primary completion
February 2028
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Søren Egstrand, MD, PhD
Herlev and Gentofte Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.